Purpose of review Significant progress has been made in the field of defining and describing the pathophysiology of wasting conditions such as cachexia. The number of new promising drugs, nutritional therapy alternatives, and exercise/rehabilitation programs is increasing. The purpose of this review is to give an overview of recent clinical findings from intervention studies investigating multimodal anabolic therapies utilizing drug, nutritional, and/or exercise interventions in order to counteract wasting.
INTRODUCTION
Muscle wasting occurs in various conditions and situations such as aging, inactivity, and cachexia. In most of these conditions, changes in muscle morphology leads to changes in functionality with great impact on patients' physical performance and quality of life (QoL) [1] . Cachexia is a wasting condition accompanying a wide array of chronic or end-stage diseases including cancer, chronic kidney disease, chronic heart disease, and chronic obstructive pulmonary disease (COPD) [2, 3] . Decreased nutritional intake, loss of appetite, increased metabolism, and severe muscle loss are the main features of the cachexia syndrome [4] .
Although the pathophysiology of wasting conditions such as cachexia is still not completely understood, much knowledge has been acquired in the past decades. The pathophysiology in cachexia is characterized by a negative protein and energy balance driven by a variable combination of reduced nutritional intake and abnormal metabolism [2] . It is caused by intricate interactions between inflammation, hypermetabolism (e.g. increased resting energy expenditure), hormonal changes, and proteolytic and lipolytic factors [5] .
Loss of skeletal muscle mass is due to reduced protein synthesis, increased degradation or an imbalance between the two [6] . Anabolic therapy stimulates metabolic pathways mainly in muscle in order to increase its quantity [examples of mediators are insulin, insulin-like growth factor-1 (IGF-1) and the mammalian target of rapamycin (mTOR) pathway]. Potential anabolic effects on muscle mass should be targeted in cachexia prevention and treatment, but anticatabolic effects in order to decrease muscle breakdown are obviously also of major importance [examples of mediators are myostatin/activin, tumor-specific factors such as zinc-(alpha) 2-glycoprotein and inflammatory cytokines]. The catabolic and antianabolic mediators might work in concert, and thus the nomenclature could sometimes be ambiguous. Additionally, multiple drugs will act on numerous biological pathways.
The definition of anabolic therapy for wasting conditions could be argued. Studies with eicosapentaenoic acid (EPA), L-carnitine [7, 8] megace [8, 9] and selumetinib [10, 11] could possibly have secondary anabolic effects partly by anti-inflammatory actions, leading to preservation of weight and/or muscle mass. Nevertheless, in this review, the choice has been to focus on recent clinical trials with direct anabolic effects on muscle.
Current nutrition, exercise and pharmacological treatment
Nutritional debilitation is a crucial part of the cachexia syndrome, and treatment should focus on avoiding negative energy and protein balance. Unfortunately, weight loss in cancer cachexia cannot be reversed by simple nutritional supplementation alone, as catabolism increases despite reduced food and energy intake. Nevertheless, appropriate caloric and protein intake is required to optimize tissue repair and muscle building. Some nutritional compounds may be important for anabolic response in muscle (e.g. glucose and essential amino acids) [12] .
Muscle dysfunction and structural alterations in wasting conditions result in reduced strength and limited mobility. Physical exercise is probably the most physiological strategy to improve muscle mass and strength due to the increased rate of synthesis of myosin heavy chain, and increased muscle fiber size and capillary density in muscle. Still, in wasting conditions, the optimal frequency, intensity and duration of exercise interventions are not fully resolved [13] [14] [15] .
The ideal pharmacological candidate for treatment of cachexia would be a compound able to increase food intake and also improve muscle mass and function, which are the main components of the cachectic syndrome. Several drugs have been evaluated, but so far, only few have reached a level of evidence that makes them applicable for clinical use. When designing effective therapies for cachexia, it seems probable that a multitargeted approach is necessary in order to manage its complex pathophysiology [16, 17] .
There are many differences between the various wasting disorders, but there are also similarities in both clinical presentation and pathophysiology. It could therefore be of interest to look at advances in different wasting conditions in order to draw benefit from knowledge extracted in adjacent disciplines. The present review will focus on trials published in the past 2 years investigating the effect of nutritional, exercise and pharmacological anabolic intervention therapies on clinical outcomes in wasting conditions.
RECENT INTERVENTION TRIALS FOR WASTING CONDITIONS
Clinical trials published in the past 2 years testing nutrition and anabolic therapies for wasting conditions are summarized in Table 1 
Ghrelin
The gut hormone ghrelin and its agonists are used as a potential treatment for wasting conditions. It has anabolic properties by binding growth hormone receptor (growth hormone secretagogue receptor-1) to stimulate growth hormone (GH) release and production of IGF-1. In addition, ghrelin mediates energy balance by its effects on the central melanocortin system, increasing appetite and decreasing basal metabolic rate [26] . A recent review concluded that there is strong evidence for ghrelin being an effective appetite stimulant, but there is less evidence concerning its effects on body composition
KEY POINTS
Muscle wasting occurs in various conditions and situations such as aging, inactivity and cachexia.
Anabolic therapy stimulates metabolic pathways mainly in muscle in order to increase its quantity.
In the past 2 years, eight studies investigating the anabolic potential of ghrelin, androgen modulators, exercise and nutrition have been published. Three of these studies were multimodal.
Most anabolic interventions demonstrate the potential to improve muscle mass, the multimodal studies seem to a greater extent also to demonstrate improvement in physical function. Only studies with clinical outcomes on wasting conditions were included.
and muscle strength due to limited numbers of trials conducted on these outcomes [27] . A short-term safety profile of ghrelin with few adverse events has been demonstrated, although large-scale trials with longer follow-up are warranted [27, 28] . Recently, a novel orally bioavailable mimic of ghrelin, anamorelin, was tested out in a doubleblind, placebo-controlled crossover pilot study in 31 patients with cancer-related cachexia [20] . Patients receiving 50 mg anamorelin per day had a significant increase in body weight (0.77 vs. À0.33 kg; P ¼ 0.016) and improved appetite after 3 days of treatment. Anamorelin seemed well tolerated, but objective measures of the contribution to lean body mass or physical function were not assessed. In a single-blind randomized clinical trial (RCT) on patients with esophageal cancer, Hiura et al. [21] reported higher food intake (18.1 vs. 12.7 kcal/kg/day; P ¼ 0.027), increased appetite and overall QoL after 7 days of intravenous ghrelin compared to placebo. The study did not investigate the effect on weight or muscle mass.
Ghrelin has also been tested on pulmonary cachexia in advanced stages of COPD. Two RCTs by Miki et al. [22, 23] have studied the effect of intravenous ghrelin on physical and pulmonary functions. After 3 weeks of treatment, none of the trials found any effect on muscle mass or body weight, but they found improved QoL symptoms (repeated-measures, P ¼ 0.049), dyspnea score, respiratory strength (N ¼ 33) [23] and peak oxygen uptake (N ¼ 20) [22] in favor of ghrelin. Additionally, one of the trials found improved exercise performance (peak VO 2 ), perhaps due to a combined multimodal intervention, as all the patients in both groups received aerobic exercise 5 days/week as part of the standard treatment [22] . The most comprehensive trial investigating ghrelin is a multicenter RCT performed by Levinson and Gertner [24] in patients with severe COPD and cachexia (N ¼ 278). They presented an increase in lean body mass and total body weight from baseline after 12 weeks of two daily doses with subcutaneous ghrelin treatment compared to placebo.
Androgen modulators
Another promising drug is the selective androgen receptor modulators (SARMs), a novel class of tissuespecific androgen receptor ligands which brings conformational alterations in the androgen receptor that alters its ability to increase muscle protein synthesis via several signaling pathways [29] .
A phase II RCT by Dobs et al. [18 & ] (N ¼ 159) focusing on efficacy and safety of the novel oral enobosarm showed a significant increase in total lean body mass (1 mg enobosarm: mean 1.5 kg AE 2.7, P < 0.001; and 3 mg enobosarm: 1.3 kg AE 3.5, P ¼ 0.0046) compared with baseline measurements after 113 days of treatment in patients with cancer cachexia [4] . The increased muscle mass was associated with improved physical function as measured by the stair climb test score.
Selective androgen receptor modulator may also potentially counteract muscle wasting in healthy elderly. This was investigated in women (>65 years) with sarcopenia (N ¼ 170) in a double-blind RCT during 6 months oral therapy with 50 mg/day of placebo [19 & ]. All participants received vitamin D (2800-5600 IU/week) and protein supplements (25-30 g protein/day) irrespective of the treatment arm. After 6 months, lean body mass increased significantly in the intervention group (mean change 1.27 vs. 0.27 kg; P < 0.001) in the placebo group. Compared to baseline, both groups showed improved strength and physical performance measures, but there were no differences between the treatment groups. This could partly be attributed to the underlying nutritional intervention. Further studies will be important to determine the synergistic effects ghrelin or SARM may have in combination with other approaches to treatment of wasting such as nutrition and physical exercise.
Testosterone is a nonselective androgen hormone. COPD patients seem vulnerable to testosterone deficiency and substitution seems to improve several exercise capacity outcomes in these patients [30] . Pison et al. [25 & ] examined a multimodal intervention in malnourished patients with chronic respiratory failure. The treatment lasted for 3 months and consisted of the combination of nutritional, exercise and oral testosterone. Compared to controls not receiving any of the interventions, patients undergoing multimodal treatment demonstrated improvements in mean differences between groups in BMI, fat free mass, peak work load and quadriceps isometric force.
Nutritional and exercise therapy
Muscle mass will remain relatively stable in healthy adults if physical activity and consumption of protein and energy is adequate, but on average 1% muscle mass is lost every year after 60 years of age [31] .
Both amino acids intake and exercise with contraction of muscles are potent anabolic stimuli for protein synthesis and muscle hypertrophy. Combining resistance exercise with amino acid ingestion for muscle protein synthesis results in synergistic anabolic effects in older people [32] , and response to resistance exercise on lean body mass and muscle strength in COPD patients seems similar to healthy controls when receiving adequate dietary supplements [33] . Wasting conditions with reduced exercise tolerance and limited mobility such as shown in patients with COPD and cancer cachexia clinically benefit from physical exercise [14, 34] . It may also be possible that interaction with exercise or nutrition is necessary for most anabolic pharmacological compounds to be sufficiently efficient, but there is not enough evidence of the impact of the combined approach with nutrition and physical exercise [35] . No unimodal clinical trials consisting of only nutrition or exercise interventions were published in the past 2 years. However, nutrition and exercise are part of the three multimodal interventions 
MULTIMODAL TREATMENT
Weight loss in cancer cachexia cannot be reversed simply by nutrient supplementation, but only aiming to improve muscle anabolism using pharmacological agents in patients with insufficient food intake seems futile. This would correspond to aiming to build muscle without adding the necessary substrate for the muscle to use.
There are still few truly multimodal clinical trials aiming to improve muscle mass and function, but the numbers are increasing. Previously published multimodal studies have shown that adding nutritional therapy to multimodal cachexia intervention (NSAID and erythropoietin) resulted in increased survival in as-treated analysis in cancer patients [36] , and the combination of four different treatments (EPA, thalidomide, L-carnitine and megestrol acetate) was superior to each intervention administrated alone in terms of increased lean muscle mass, resting energy expenditure and reduced fatigue [37] .
Three RCTs presented in Table 1 were identified as multimodal [19 & ,22,25 & ] -two on pulmonary wasting disease [22,25 & ] and one on sarcopenia [19 & ]. Papanicolaou et al. [19 & ] gave vitamin D and protein supplements to both groups in addition to SARM in the treatment arm, whereas Miki et al. [22] gave exercise rehabilitation to both groups in addition to ghrelin in the treatment arm. Pison et al. [25 & ] gave nutrition and exercise in addition to testosterone in the intervention arm only. These two studies with longest duration of intervention (3 and 6 months) found increased muscle mass followed by improved physical function [19 & ,25 & ]. The final study, lasting for only 3 weeks and including a low number of patients, did not show any effect on muscle mass or weight. However, adding pulmonary rehabilitation to ghrelin treatment increased peak oxygen uptake in the intervention group [22] .
Limited numbers of multimodal studies were conducted in the past 2 years, but supplementary effects in improving muscle mass/body weight and muscle functions by combining treatments seem to be observed [19 & ,25 & ]. Interestingly, protein and vitamin D intervention led to improved muscle strength in both arms compared to baseline, whereas only the ghrelin arm showed effect on muscle mass [19 & ]. This indicates that nutritional substrate is needed to achieve muscles strength independent of increased muscle mass.
ONGOING STUDIES
Both ghrelin (ClinicalTrials.gov: NCT01387269, NCT01387282) and SARM (ClinicalTrials.gov: NCT01355497, NCT01355484, NCT00467844) are now in phase III clinical testing of cancer patients. Endpoints in these trials are change in muscle mass and/or physical function. The anabolic/catabolic transforming agent with beta-1 blocking activity MT-102 is of great interest, and trials on advanced cancer patients are ongoing (ClinicalTrials.gov: NCT01238107) [38, 39] . Few multimodal studies are reported in this topical review, but more studies are in the pipeline, including a combination of drugs, nutrition and exercise (ClinicalTrials.gov: NCT01419145, NCT01127386, NCT00625742).
RELEVANT OUTCOMES
Due to the multifactorial nature of wasting disorders and the diversity of underlying diseases included in this review, a great variety of outcomes have been assessed. Muscle loss is a key feature of cancer cachexia and other wasting conditions, and change in muscle mass is thus a highly relevant outcome in these trials. Only one study included in this review did not assess muscularity. However, this anamorelin (ghrelin) study observed effect on body weight after 3 days of treatment [20] . Although body weight is important, increased weight based on water and fat mass may not be relevant without subsequent increase in lean body mass. The three other studies intervening with ghrelin in this review demonstrate no effect on muscle mass, but they are short in duration ( 3 weeks) and only a small number of patients are included (N < 50) [21] [22] [23] . Anamorelin is currently investigated in several large trials in which the interventions last for 12 weeks and the outcome is lean body mass.
As improvement in muscularity is anticipated followed by an increase in physical performance, respiratory functions, QoL and reduced treatmentrelated toxicity, these are other outcomes assessed in trials included in this review. In addition, survival, nutritional intake and appetite, catabolic drive and emotional function are considered of importance (see Table 1 ). Due to the diversity of outcomes, underlying conditions and duration of interventions, it is not possible to highlight any intervention as being most promising considering anabolic impact.
CONCLUSION
In the past 2 years, eight clinical trials considering anabolic treatments for wasting conditions were published. These include four studies with patients suffering from COPD; three with cancer patients and one in which patients had age-related sarcopenia. Only three trials had multimodal interventions. The five unimodal intervention studies showed effect on various outcomes, but it may seem that multimodal interventions are beneficial to add effects of physical functions in addition to increased muscle mass.
It has been demonstrated in previous studies that anabolic potential might exist if effective interventions are implemented at the initial stages of cancer cachexia (<90-day survival) [40 & ]. Some optimism is appropriate in finding future successful treatment strategies to counteract the catabolic drive and improve treatment and prognosis of these patients. Several anabolic therapies have the potential to be of significance; however, as per today, there is no standard anabolic treatment for wasting conditions in clinical setting.
